Risk Stratification Of Older People In Hospital: Validation And Influence On Clinical Decision Making
Funder
National Health and Medical Research Council
Funding Amount
$291,067.00
Summary
Older people in hospital are at high risk of adverse outcomes, a vulnerability commonly referred to as frailty. In community-dwelling older people, frailty status can be measured precisely with a Frailty Index score. This research aims to develop a Frailty Index from a standardised comprehensive geriatric assessment instrument used in the routine care of many patients in hospital. This would assist clinicians to identify vulnerable older inpatients, improving their care in the acute setting.
ESTIMATION OF INDIGENOUS MORTALITY WHERE DESIGNATION OF INDIGENOUS STATUS ON DEATH CERTIFICATES IS UNRELIABLE
Funder
National Health and Medical Research Council
Funding Amount
$158,840.00
Summary
Mortality of indigenous Australians is regarded as unacceptably high compared to other Australians and compared to indigenous minorities in other similar countries. Indigenous mortality is based on data from WA, SA and NT, although some of the data are unreliable. There are few reliable data available in Qld, NSW, Vic or Tas because Indigenous status is significantly under-recorded on the death certificate. The objective of the research is to devise and validate indirect methods for estimating i ....Mortality of indigenous Australians is regarded as unacceptably high compared to other Australians and compared to indigenous minorities in other similar countries. Indigenous mortality is based on data from WA, SA and NT, although some of the data are unreliable. There are few reliable data available in Qld, NSW, Vic or Tas because Indigenous status is significantly under-recorded on the death certificate. The objective of the research is to devise and validate indirect methods for estimating indigenous mortality in sub-populations where there are significant proportions of indigenous people, and where designation of indigenous status on death certificate is unreliable. This would permit assessment of mortality differentials and trends in a significant number of Aboriginal and Torres Strait Islander communities in Qld, NSW, Vic and possibly Tas and provide new perspectives in the study of determinants of mortality in indigenous populations through comparisons of communities with relatively high and relatively low mortality, and allow population-based evaluation of the effectiveness of services and programs through surveillence of mortality trends and differentials. The methods rely on the basic premise that the total mortality of a population is contributed to by the mortality of its components in relation to their proportion of the total population. The units of analyses will be mainly municipalities. Mortality and proportion indigenous will be used in the comparison of municipalities with similar socio-economic and geographic characteristics, and mortality by municipality will be statistically modelled using various characteristics of these populations, including proportion indigenous (using ABS data). Methods will be validated by employing them on selected WA, SA and NT mortality data where designation of indigenous staus is considered reliable. Mortality estimates will then be made for indigenous communities in NSW, Qld, and other states.Read moreRead less
Validating Novel Biomarkers Relevant To Major Depression
Funder
National Health and Medical Research Council
Funding Amount
$515,550.00
Summary
Depression prevention and treatment are public health priorities; therefore, it is critical to improve and personalise treatments, which can only be achieved by advancing knowledge of its underlying biology. This research project will contribute to validating potentially relevant genes for MDD risk or antidepressant response and to provide the scientific foundation for future strategies to test their products as MDD biomarkers in the clinical setting.
Development And Validation Of A Latent Tuberculosis Diagnostic
Funder
National Health and Medical Research Council
Funding Amount
$534,865.00
Summary
Globally, tuberculosis is a leading cause of death with 9.6 million new diagnoses in 2014. The diagnosis of latent TB infection is important, but is difficult to make because current assays are suboptimal. We have developed a very simple assay which detects responses to TB antigens by co-expression of two surface markers expressed by CD4+ T cells. We propose to develop this into a highly standardised kit for the diagnosis of TB with our commercial partner Cytognos.
Validation Of A Multiplexed Blood Based Screening Assay For The Diagnosis Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$556,712.00
Summary
Colorectal cancer (CRC) is the second most common cancer in Australia with poor patient outcome due to late detection of the disease. We have developed a simple blood based test that can diagnose individuals with CRC at an early stage when the chance of cure is greater than 80%.
The Validity Of ‘8 Instruments’ Used To Include Quality Of Life In Economic Evaluation In 8 Disease Areas And 6 Countries
Funder
National Health and Medical Research Council
Funding Amount
$856,212.00
Summary
The Quality of Life is incorporated in the economic evaluation of health services using different ‘utility instruments’. Small scale comparative studies reveal large discrepancies between measurements. Very few studies combine multiple utility and disease specific instruments and to date no studies have compared utility instruments with scales measuring subjective wellbeing (happiness) or human capabilities. This project will mount the largest cross national survey to date of these questions.
Risk prediction models incorporating multiple risk factors (including genetic markers) are a recognised method to identify individuals at high risk of developing breast or colorectal cancer, but it is uncertain which model(s) currently perform best in a population setting. We aim to compare the predictive ability of each available model. Knowing which model performs best will facilitate early diagnosis, reduce overall costs by better targeting interventions and improve cancer survival.